and the potential launch or commercialization of any of Companys product candidates or products and our strategic and product development objectives and goals, and the other factors discussed under the caption Risk Factors in our Annual Report on Form 10-K for the year ended December 31, 2024 and Quarterly Report on Form 10-Q for the quarter ended June 30, 2025, filed with the Securities and Exchange Commission on August 12, 2025 and in our other filings with the SEC
Skin and Healthy Aging Goals Adults exploring physician-guided wellness programs that include peptides studied for skin and tissue support
At the same time, this is not the whole story
Separate research has shown that weight often returns after stopping GLP-1 therapy, and that what comes back is not always what left: regained weight can skew toward fat rather than muscle (external literature, e.g
Registered pursuant to the ACVM Act 1997, No